KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Alnylam Pharmaceuticals (ALNY) EBT (2016 - 2025)

Historic EBT for Alnylam Pharmaceuticals (ALNY) over the last 16 years, with Q4 2025 value amounting to $86.3 million.

  • Alnylam Pharmaceuticals' EBT rose 14447.41% to $86.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was $287.5 million, marking a year-over-year increase of 17618.52%. This contributed to the annual value of $323.2 million for FY2025, which is 18563.15% up from last year.
  • According to the latest figures from Q4 2025, Alnylam Pharmaceuticals' EBT is $86.3 million, which was up 14447.41% from $239.0 million recorded in Q3 2025.
  • In the past 5 years, Alnylam Pharmaceuticals' EBT registered a high of $239.0 million during Q3 2025, and its lowest value of -$405.9 million during Q3 2022.
  • Moreover, its 5-year median value for EBT was -$180.3 million (2021), whereas its average is -$125.1 million.
  • Over the last 5 years, Alnylam Pharmaceuticals' EBT had its largest YoY gain of 31991.75% in 2025, and its largest YoY loss of 21662.94% in 2025.
  • Over the past 5 years, Alnylam Pharmaceuticals' EBT (Quarter) stood at -$260.3 million in 2021, then grew by 20.47% to -$207.0 million in 2022, then skyrocketed by 33.49% to -$137.7 million in 2023, then plummeted by 40.87% to -$194.0 million in 2024, then surged by 144.47% to $86.3 million in 2025.
  • Its EBT stands at $86.3 million for Q4 2025, versus $239.0 million for Q3 2025 and -$35.4 million for Q2 2025.